Silmitasertib clinical trials
Also written CX-4945.
How each study uses silmitasertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the silmitasertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 3
Senhwa Biosciences, Inc. (5) · Cylene Pharmaceuticals (2) · Milton S. Hershey Medical Center (1) · Pediatric Brain Tumor Consortium (1) · University of Arizona (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses silmitasertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsRecruitingPhase 1/2Milton S. Hershey Medical CenterNCT06541262Written as Silmitasertib
- Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have SurgeryTerminatedPhase 1/2Pediatric Brain Tumor ConsortiumNCT03904862Written as CX 4945
- CX-4945 in Viral Community Acquired PneumoniaTerminatedPhase 2Senhwa Biosciences, Inc.NCT06202521Written as CX-4945 (SARS-CoV-2 domain)
- Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)CompletedPhase 1Senhwa Biosciences, Inc.NCT03897036Written as CX-4945
- A Study of Silmitasertib (CX-4945) in Healthy SubjectCompletedPhase 1Senhwa Biosciences, Inc.NCT05817708Written as CX-4945
- Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19CompletedPhase 2Senhwa Biosciences, Inc.NCT04663737Written as Silmitasertib
- Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)TerminatedPhase 2University of ArizonaNCT04668209Written as Silmitasertib
- Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of CholangiocarcinomaCompletedPhase 1/2Senhwa Biosciences, Inc.NCT02128282Written as CX-4945
- Dose-escalation Study of Oral CX-4945Status unknownPhase 1Cylene PharmaceuticalsNCT00891280Written as CX-4945 oral formulation
- Study of CX-4945 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownPhase 1Cylene PharmaceuticalsNCT01199718Written as CX-4945
Codes
What other systems call silmitasertib · ClinicalTrials.gg INT005765
- MeSH (NLM) C555142silmitasertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) C6RWP0N0L2SILMITASERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27076934silmitasertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98054SilmitasertibOne source FDA
- DrugBank DB15408One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C555142 | silmitasertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | C6RWP0N0L2 | SILMITASERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27076934 | silmitasertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98054 | Silmitasertib | One source FDA |
| DrugBank | DB15408 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.